ATE150648T1 - Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) - Google Patents
Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)Info
- Publication number
- ATE150648T1 ATE150648T1 AT92900612T AT92900612T ATE150648T1 AT E150648 T1 ATE150648 T1 AT E150648T1 AT 92900612 T AT92900612 T AT 92900612T AT 92900612 T AT92900612 T AT 92900612T AT E150648 T1 ATE150648 T1 AT E150648T1
- Authority
- AT
- Austria
- Prior art keywords
- osteoporosis
- grf
- pth
- releasing factor
- conjunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61754390A | 1990-11-26 | 1990-11-26 | |
PCT/US1991/008106 WO1992009304A1 (en) | 1990-11-26 | 1991-11-01 | Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE150648T1 true ATE150648T1 (de) | 1997-04-15 |
Family
ID=24474060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92900612T ATE150648T1 (de) | 1990-11-26 | 1991-11-01 | Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) |
Country Status (13)
Country | Link |
---|---|
US (1) | US5164368A (de) |
EP (1) | EP0559751B1 (de) |
JP (1) | JP2557779B2 (de) |
AT (1) | ATE150648T1 (de) |
AU (1) | AU645874B2 (de) |
CA (1) | CA2096350C (de) |
DE (1) | DE69125394T2 (de) |
DK (1) | DK0559751T3 (de) |
ES (1) | ES2099245T3 (de) |
FI (1) | FI106776B (de) |
IE (1) | IE913858A1 (de) |
NZ (1) | NZ240482A (de) |
WO (1) | WO1992009304A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9408019A (pt) * | 1993-11-09 | 1997-08-26 | Merck & Co Inc | Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto |
US5492920A (en) * | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US6074840A (en) * | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5731317A (en) * | 1995-03-10 | 1998-03-24 | Merck & Co., Inc. | Bridged piperidines promote release of growth hormone |
US5700775A (en) * | 1995-03-24 | 1997-12-23 | Gutniak; Mark K. | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury |
US5559128A (en) * | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
BR9709499A (pt) * | 1996-05-31 | 1999-08-10 | Novo Nordisk As | Processo para prevenção ou tratamento de osteoporose e de perturbações relacionamas uso de um componente de hormónio do crescimento uso de uma composição com uma ação de anti-reabsorção sobre os ossos e produtos |
AU2002300896B2 (en) * | 1997-06-19 | 2006-03-30 | Nps Pharmaceuticals, Inc. | Method of enhancing bone mineral density |
SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
EP1007673B1 (de) | 1997-07-30 | 2008-12-17 | Emory University | Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
EP1119251A4 (de) * | 1998-10-07 | 2004-03-24 | Univ Arkansas | Verfahren für das screening auf wirkstoffe für die anabole knochentherapie, die die apoptosis kontrollieren, und ihre verwendung |
WO2000028982A2 (en) | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
US7244709B2 (en) * | 2004-05-10 | 2007-07-17 | Nastech Pharamecutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
CN102711476B (zh) | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
EP2509996A1 (de) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870094A (en) * | 1984-05-02 | 1989-09-26 | Uniroyal Chemical Company, Inc. | Substituted imidazoles and triazoles |
US4870054A (en) * | 1985-09-27 | 1989-09-26 | Recker Robert R | Treatment for osteoporosis using GRF or a biologically active analog thereof |
US4710382A (en) * | 1985-09-27 | 1987-12-01 | Recker Robert R | Treatment for osteoporosis using hGRF(1-40)NH2 |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
US4833123A (en) * | 1987-10-08 | 1989-05-23 | Sumitomo Chemical Company Limited | Yellow dye-donor element used in thermal transfer and thermal transfer and thermal transfer sheet using it |
AU617426B2 (en) * | 1988-01-29 | 1991-11-28 | Upjohn Company, The | Growth hormone releasing factor analogs |
-
1991
- 1991-11-01 CA CA002096350A patent/CA2096350C/en not_active Expired - Fee Related
- 1991-11-01 DK DK92900612.0T patent/DK0559751T3/da active
- 1991-11-01 DE DE69125394T patent/DE69125394T2/de not_active Expired - Fee Related
- 1991-11-01 JP JP4501851A patent/JP2557779B2/ja not_active Expired - Fee Related
- 1991-11-01 AU AU90735/91A patent/AU645874B2/en not_active Ceased
- 1991-11-01 AT AT92900612T patent/ATE150648T1/de not_active IP Right Cessation
- 1991-11-01 WO PCT/US1991/008106 patent/WO1992009304A1/en active IP Right Grant
- 1991-11-01 EP EP92900612A patent/EP0559751B1/de not_active Expired - Lifetime
- 1991-11-01 ES ES92900612T patent/ES2099245T3/es not_active Expired - Lifetime
- 1991-11-04 US US07/787,051 patent/US5164368A/en not_active Expired - Lifetime
- 1991-11-05 IE IE385891A patent/IE913858A1/en not_active IP Right Cessation
- 1991-11-05 NZ NZ240482A patent/NZ240482A/en unknown
-
1993
- 1993-05-26 FI FI932385A patent/FI106776B/fi active
Also Published As
Publication number | Publication date |
---|---|
AU645874B2 (en) | 1994-01-27 |
EP0559751A4 (en) | 1994-07-13 |
EP0559751A1 (de) | 1993-09-15 |
NZ240482A (en) | 1997-06-24 |
CA2096350A1 (en) | 1992-05-27 |
JP2557779B2 (ja) | 1996-11-27 |
DK0559751T3 (da) | 1997-10-06 |
FI932385A0 (fi) | 1993-05-26 |
US5164368A (en) | 1992-11-17 |
ES2099245T3 (es) | 1997-05-16 |
CA2096350C (en) | 2001-10-16 |
JPH06502863A (ja) | 1994-03-31 |
DE69125394D1 (de) | 1997-04-30 |
FI106776B (fi) | 2001-04-12 |
DE69125394T2 (de) | 1997-08-21 |
IE913858A1 (en) | 1992-06-03 |
WO1992009304A1 (en) | 1992-06-11 |
AU9073591A (en) | 1992-06-25 |
FI932385A (fi) | 1993-05-26 |
EP0559751B1 (de) | 1997-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE150648T1 (de) | Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) | |
RU2224539C2 (ru) | Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр) | |
CA2124792A1 (en) | Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone | |
DE3866817D1 (de) | Knochenzement zur kontrollierten abgabe von wirkstoffen. | |
DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
YU46794A (sh) | Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena | |
FI952701A0 (fi) | Metallisen kirurgisen istukkaan käsittelymenetelmä | |
DE69113470D1 (de) | Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln. | |
CA2032123A1 (fr) | Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus | |
DK0725648T3 (da) | Leverspecifikke farmaceutiske aktivstoffer | |
IL99732A0 (en) | Vascularization promoting implant material | |
DK336986A (da) | Fremgangsmaade til fremstilling af taerre biologisk aktive rekombinante vaeksthormoner | |
SE8405596D0 (sv) | A method of producing a mono- or multilayered prothesis material and the material hereby obtained | |
ES2101833T3 (es) | Utilizacion de igf-i humano. | |
DE3868910D1 (de) | Implantat zur befestigung von zahnprothesen. | |
NO305581B1 (no) | Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose | |
RU93005051A (ru) | Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации | |
ATE447410T1 (de) | Verwendung von humanem parathyroid-hormon | |
GEP20033095B (en) | Parathyroid Hormone Analogues for the Treatment of Osteoporosis | |
FR2655276B1 (fr) | Microemulsions concentrees de matieres organiques diluables sous forme d'emulsions stables et leur procede de preparation. | |
DE69316013D1 (de) | Verwendung von phosphinate zur behandlung der osteoporose | |
CA2074166A1 (en) | Method for treating intestinal diseases | |
ATA223591A (de) | Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten | |
ROGACHEVA | Effects of calcitonin and retabolil on rat femur in hypokinesia(Abstract Only) | |
Shiota et al. | The Promotion of Calcification by Calcitonin in Fracture Callus in Rats Treated with High Doses of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |